





King, Valerie A.

From: Kimberly Prchal [Kimberly.Prchal@mdsps.com]
Sent: Wednesday, February 12, 2003 3:30 PM
To: Hans-Juergen.Roethig@pmusa.com; martin.unverdorben@pmusa.com;
Bettie.L.Nelson@pmusa.com; Jan.Oey@pmusa.com; Mohamadi.Sarkar@pmusa.com;
valerie.a.king@pmusa.com; paul.mendes@pmusa.com
Cc: Michael Szwaneke; Chad Briscoe; Peggy Ruhn; Nancy Wang; Henry Cheng; Yuli Xie; Megan
Mccrory; Robert Earl; Philip Bach; James Cunningham; Mary Hetrick
Subject: Study Dates
Sensitivity: Confidential

   
2981 Confirmed Dates, 3468 Revised Dates, 4271 Confirmed Dates, 4271 Screening
Final.do... V4.doc Final.do... Information.doc... All,

Attached are the revised study dates for the short-term Series K studies. The initial study SeriesK/01/03 (AA02981) has been moved to June 2003. The second study SeriesK/02/03 (AA03468) has been moved to August 2003. IRB dates and final document receipt have also been included.

Also attached are the confirmed dates for the short-term ACCORD JLI Menthol study (ECHJLI/01/03 - AA04271), to run in April 2003, and the screening dates for the Menthol study. Please note that the IRB dates has been revised to 11 March, with final documents needed on 05 March.

As you mentioned in the conference call this morning, we may be looking at a continuation onto the Menthol. Philip Morris may have a decision on this on Friday.

This morning, MDS was also asked to provide another set of dates for a 10-day study, due to possibly not having animal data back in time for the initial Series K study (Jun). (Phil, would you be able to provide 10 days in September 2003? To be used if Jun study does not go). Dates for a continuation on to both Series K studies will also be needed, but at a later date.

Thanks
Kim

Kimberly M. Prchal
Senior Project Manager
MDS Pharma Services - Lincoln, NE
kimberly.prchal@mdsps.com
402.437.4773